Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Codman Institute for Clinical Effectiveness in Surgery, Massachusetts General Hospital, Boston, MA, USA.
Gastric Cancer. 2019 May;22(3):446-455. doi: 10.1007/s10120-018-0869-z. Epub 2018 Aug 22.
The prognosis of gastric cancer patients is better in Asia than in the West. Genetic, environmental, and treatment factors have all been implicated. We sought to explore the extent to which the place of birth and the place of treatment influences survival outcomes in Korean and US patients with localized gastric cancer.
Patients with localized gastric adenocarcinoma undergoing potentially curative gastrectomy from 1989 to 2010 were identified from the SEER registry and two single institution databases from the US and Korea. Patients were categorized into three groups: Koreans born/treated in Korea (KK), Koreans born in Korea/treated in the US (KUS), and White Americans born/treated in the US (W), and disease-specific survival rates compared.
We identified 16,622 patients: 3,984 (24.0%) KK, 1,046 (6.3%) KUS, and 11,592 (69.7%) W patients. KK patients had longer unadjusted median (not reached) and 5-year disease-specific survival (81.6%) rates than KUS (87 months, 55.9%) and W (35 months, 39.2%; p < 0.001 for all comparisons) patients. This finding persisted on subset analyses of patients with stage IA tumors, without cardia/GEJ tumors, with > 15 examined lymph nodes, and treated at a US center of excellence. On multivariable analysis, KUS (HR 2.80, p < 0.001) and W (HR 5.79, p < 0.001) patients had an increased risk of mortality compared to KK patients.
Both the place of birth and the place of treatment significantly contribute to the improved prognosis of patients with gastric cancer in Korea relative to those in the US, implicating both nature and nurture in this phenomenon.
亚洲地区胃癌患者的预后优于西方国家。遗传、环境和治疗因素都与之相关。我们试图探讨出生地和治疗地点在多大程度上影响韩国和美国局部胃癌患者的生存结局。
从 SEER 登记处和美国和韩国的两个单机构数据库中确定了 1989 年至 2010 年间接受潜在治愈性胃切除术的局部胃腺癌患者。将患者分为三组:出生/在韩国治疗的韩国人(KK)、出生于韩国/在美国治疗的韩国人(KUS)和出生/在美国治疗的白人美国人(W),并比较了疾病特异性生存率。
我们确定了 16622 名患者:3984 名(24.0%)KK、1046 名(6.3%)KUS 和 11592 名(69.7%)W 患者。KK 患者的未调整中位(未达到)和 5 年疾病特异性生存率(81.6%)均长于 KUS(87 个月,55.9%)和 W(35 个月,39.2%;所有比较均 p<0.001)患者。在肿瘤分期为 IA、无贲门/胃食管交界肿瘤、有>15 个检查淋巴结和在美国卓越中心治疗的患者的亚组分析中,这一发现仍然存在。多变量分析显示,与 KK 患者相比,KUS(HR 2.80,p<0.001)和 W(HR 5.79,p<0.001)患者的死亡风险增加。
出生地和治疗地点都显著影响了韩国胃癌患者的预后,相对于美国患者有所改善,这表明自然和养育都对这一现象有影响。